The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murakami, K.
Right arrow Articles by Pober, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murakami, K.
Right arrow Articles by Pober, J. S.
The Journal of Immunology, 1999, 163: 2667-2673.
Copyright © 1999 by The American Association of Immunologists

Human Endothelial Cells Augment Early CD40 Ligand Expression in Activated CD4+ T Cells Through LFA-3-Mediated Stabilization of mRNA1

Kenji Murakami2,*, Weilie Ma*, Ramsay Fuleihan{dagger} and Jordan S. Pober3,*

* Molecular Cardiobiology Program, Boyer Center for Molecular Medicine, and {dagger} Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06510

Human endothelial cells (EC) augment CD40 ligand (CD40L) expression on PHA-activated CD4+ T cells at early times (e.g., 4–6 h). Fixed EC, devoid of mRNA, are comparable to living EC in their capacity to augment early CD40L expression on CD4+ T cells. Fixed EC increase T cell mRNA expression of both IL-2 and CD40L compared with PHA alone at 6 h. EC are unable to increase the rate of transcription of CD40L compared with PHA alone as measured with a promoter-reporter gene, although they do increase transcription of an IL-2 promoter-reporter gene. Fixed EC prolong the half-life of CD40L mRNA >2-fold. Inclusion of anti-human LFA-3 (CD58) mAb or pretreatment of EC with an LFA-3 antisense oligonucleotide blocks EC-induced increases in CD40L expression, whereas mAb to ICAM-1 or pretreatment with ICAM-1 antisense oligonucleotide does not. Moreover, mAb to LFA-3 reverses the capacity of EC to prolong the half-life of CD40L mRNA, whereas mAb to ICAM-1, even in combination with mAb to ICAM-2, does not. We conclude that EC use LFA-3 to increase early CD40L protein expression on newly activated CD4+ T cells by stabilizing CD40L mRNA.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
B. J. Hamilton, X.-W. Wang, J. Collins, D. Bloch, A. Bergeron, B. Henry, B. M. Terry, M. Zan, A. J. Mouland, and W. F. C. Rigby
Separate cis-trans Pathways Post-transcriptionally Regulate Murine CD154 (CD40 Ligand) Expression: A NOVEL FUNCTION FOR CA REPEATS IN THE 3'-UNTRANSLATED REGION
J. Biol. Chem., September 12, 2008; 283(37): 25606 - 25616.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
D. Daoussis, I. Antonopoulos, A. P. Andonopoulos, and S.-N. C. Liossis
Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis
Rheumatology, February 1, 2007; 46(2): 227 - 231.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Choi, J. Walker, S. Boichuk, N. Kirkiles-Smith, N. Torpey, J. S. Pober, and L. Alexander
Human Endothelial Cells Enhance Human Immunodeficiency Virus Type 1 Replication in CD4+ T Cells in a Nef-Dependent Manner In Vitro and In Vivo
J. Virol., January 1, 2005; 79(1): 264 - 276.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Singh, J. Laughlin, P. A. Kosinski, and L. R. Covey
Nucleolin Is a Second Component of the CD154 mRNA Stability Complex That Regulates mRNA Turnover in Activated T Cells
J. Immunol., July 15, 2004; 173(2): 976 - 985.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
D. Daoussis, A. P. Andonopoulos, and S.-N. C. Liossis
Targeting CD40L: a Promising Therapeutic Approach
Clin. Vaccine Immunol., July 1, 2004; 11(4): 635 - 641.
[Full Text]


Home page
J. Immunol.Home page
R. Zhang, C. J. Fichtenbaum, D. A. Hildeman, J. D. Lifson, and C. Chougnet
CD40 Ligand Dysregulation in HIV Infection: HIV Glycoprotein 120 Inhibits Signaling Cascades Upstream of CD40 Ligand Transcription
J. Immunol., February 15, 2004; 172(4): 2678 - 2686.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Chougnet
Role of CD40 Ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells
J. Leukoc. Biol., November 1, 2003; 74(5): 702 - 709.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. J. Hamilton, A. Genin, R. Q. Cron, and W. F. C. Rigby
Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression
Mol. Cell. Biol., January 15, 2003; 23(2): 510 - 525.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. A. Kosinski, J. Laughlin, K. Singh, and L. R. Covey
A Complex Containing Polypyrimidine Tract-Binding Protein Is Involved in Regulating the Stability of CD40 Ligand (CD154) mRNA
J. Immunol., January 15, 2003; 170(2): 979 - 988.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L.-P. Berg, M. J. James, M. Alvarez-Iglesias, S. Glennie, R. I. Lechler, and F. M. Marelli-Berg
Functional Consequences of Noncognate Interactions Between CD4+ Memory T Lymphocytes and the Endothelium
J. Immunol., April 1, 2002; 168(7): 3227 - 3234.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
U. Schonbeck and P. Libby
CD40 Signaling and Plaque Instability
Circ. Res., December 7, 2001; 89(12): 1092 - 1103.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Barnhart, P. A. Kosinski, Z. Wang, G. S. Ford, M. Kiledjian, and L. R. Covey
Identification of a Complex that Binds to the CD154 3' Untranslated Region: Implications for a Role in Message Stability During T Cell Activation
J. Immunol., October 15, 2000; 165(8): 4478 - 4486.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.